Join the Crohn's Disease group to help and get support from people like you.
Crohn's Disease News (Page 2)
Related terms: Crohns
Histologic Inflammation With IBD Tied to Serious Infections
FRIDAY, Dec. 8, 2023 – Histologic inflammation with inflammatory bowel disease (IBD) is an independent risk factor for serious infections, according to a study published online Oct. 29 in Clinical ...
Higher Visceral Adipose Tissue May Need Higher Infliximab Levels for IBD Remission
WEDNESDAY, Nov. 15, 2023 – Patients with inflammatory bowel disease (IBD) and high visceral adipose tissue (VAT) may have more difficulty achieving higher infliximab levels necessary to achieve...
Subtle Changes Could Predict Inflammatory Bowel Disease Years Before Symptoms Hit
MONDAY, Nov. 13, 2023 (Healthday News) – Inflammatory bowel disease starts to develop years before patients come down with symptoms, a new study suggests. Gut changes can be detected in blood tests...
Inflammatory Bowel Disease Increases Risk for Later Arrhythmias
MONDAY, Nov. 6, 2023 – Patients with inflammatory bowel disease (IBD) overall, as well as Crohn disease (CD) and ulcerative colitis (UC) individually, have an increased risk for developing later...
FDA Approves Wezlana (ustekinumab-auub), an Interchangeable Biosimilar to Stelara
October 31, 2023 – Today, the U.S. Food and Drug Administration approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara (ustekinumab) for multiple inflammatory...
Monthly News Roundup - October 2023
FDA Clears Loqtorzi as First Treatment for Nasopharyngeal Carcinoma (NPC) In October, the U.S. Food and Drug Administration (FDA) approved Coherus BioSciences’ Loqtorzi (toripalimab-tpzi) to treat a...
FDA Approves Zymfentra (infliximab-dyyb) Subcutaneous Formulation for the Treatment of People With Inflammatory Bowel Disease
JERSEY CITY, N.J.--(BUSINESS WIRE) October 23, 2023 --Today, Celltrion USA announced that the U.S. Food and Drug Administration (FDA) has approved Zymfentra (infliximab-dyyb) for maintenance therapy...
ACG: Prophylactic Low-Dose Aspirin in Pregnancy Does Not Increase IBD Activity
THURSDAY, Oct. 26, 2023 – Use of low-dose aspirin (LDA) among pregnant women with inflammatory bowel disease (IBD) is not associated with an increased risk for disease activity, according to a study...
ACG: Intestinal Ultrasound Monitoring Cuts Time to Treatment Change in IBD
WEDNESDAY, Oct. 25, 2023 – For patients with inflammatory bowel disease (IBD), monitoring by intestinal ultrasound (IUS) results in reduced time to treatment change and to remission, according to a...
COVID Might Raise Odds for Immune Disorders Like Crohn's, Alopecia
TUESDAY, Oct. 10, 2023 – In rare cases, some patients may develop an autoimmune disease following a bout of COVID, Korean researchers report. Conditions such as alopecia (hair loss), psoriasis,...
Autoimmune, Autoinflammatory Connective Tissue Disorders Increased After COVID-19
TUESDAY, Oct. 10, 2023 – COVID-19 is associated with an increased risk for autoimmune and autoinflammatory connective tissue disorders, according to a study published online Oct. 6 in JAMA Network...
FDA Grants Interchangeable Designation to Pfizer’s Biosimilar Abrilada
NEW YORK, October 5, 2023 – Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has designated Abrilada™ (adalimumab-afzb) as an interchangeable biosimilar to Hum...
Inflammatory Bowel Disease Tied to Higher Risk for Gout
TUESDAY, Oct. 3, 2023 – Inflammatory bowel disease (IBD) is strongly associated with gout, according to a study published online Sept. 1 in JGH Open. Osama Hamid, M.B.B.S., from the Cleveland...
Statin Use Linked to Reduced Risk for CRC Incidence, Mortality in Patients With IBD
THURSDAY, Sept. 7, 2023 – For patients with inflammatory bowel disease (IBD), statin use is associated with a reduced risk for colorectal cancer (CRC) incidence and mortality, according to a study...
FDA Approves Tyruko (natalizumab-sztn), a Biosimilar to Tysabri
August 24, 2023 – The U.S. Food and Drug Administration today approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection for the treatment of adults with relapsing...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Crohn's Disease - Maintenance, Inflammatory Bowel Disease
Related drug support groups
Humira, Remicade, Stelara, Entyvio, cholestyramine, Skyrizi, adalimumab, budesonide